Nine Monthly Results Results Snapshot
Figures in Cr
No Consolidated Results Declared by Vanta Bioscience
Nine Monthly Analysis Highlights
Net Sales
YoY Growth in nine months ended Mar 2023 is -16.29% vs -53.48% in Mar 2023
Consolidate Net Profit
YoY Growth in nine months ended Mar 2023 is 4.17% vs -34.30% in Mar 2023
Operating Profit (PBDIT) excl Other Income
YoY Growth in nine months ended Mar 2023 is 0.00% vs -1,161.90% in Mar 2023
Interest
YoY Growth in nine months ended Mar 2023 is -22.74% vs -11.36% in Mar 2023
Operating Profit Margin (Excl OI)
YoY Growth in nine months ended Mar 2023 has fallen from Mar 2023
Compare Nine Monthly Results Of Vanta Bioscience With
Figures in Cr
No Consolidated Results Declared by Vanta Bioscience
Nine Monthly - Net Sales
Net Sales 3.75 Cr
in Mar 2023Figures in Cr
YoY Growth in nine months ended Mar 2023 is -16.29% vs -53.48% in Mar 2023
Nine Monthly - Consolidate Net Profit
Consolidate Net Profit -5.74 Cr
in Mar 2023Figures in Cr
YoY Growth in nine months ended Mar 2023 is 4.17% vs -34.30% in Mar 2023
Nine Monthly - Operating Profit (PBDIT)
Operating Profit (PBDIT) -2.23 Cr
in Mar 2023Figures in Cr
YoY Growth in nine months ended Mar 2023 is 0.00% vs -1,161.90% in Mar 2023
Nine Monthly - Interest
Interest 4.28 Cr
in Mar 2023Figures in Cr
YoY Growth in nine months ended Mar 2023 is -22.74% vs -11.36% in Mar 2023
Nine Monthly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) -59.47%
in Mar 2023Figures in %
YoY Growth in nine months ended Mar 2023 has fallen from Mar 2023
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
